Immutep Ltd · ASX:IMM
Immutep — BioCentury 25th Annual NewsMakers in the Biotech Industry Conference (September 2018)
29 slides from Immutep's conference presentation, Sep 7, 2018
Slide 1: The global leader in developing LAG-3 therapeutics
For personal use only The global leader in developing LAG-3 therapeutics BioCentury 25th Annual NewsMakers in the Biotech Industry Conference New York 7th September 2018 (ASX: IMM, NASDAQ: IMMP)
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 3: Company Snapshot
Company Snapshot For personal use only Capital Structure • Globally active biotechnology company with IMM (Australian Securities Exchange) operations in Australia, Europe and U.S. Ticker symbols IMMP (NASDAQ - ADRs) • Four LAG-3 related product candidates in Securities on issue 3.0 billion ordinary
Slide 4: LAG-3 Overview & Product Candidates
For personal use only LAG-3 Overview & Product Candidates 4
Slide 5: LAG-3 as a Therapeutic Target
LAG-3 as a Therapeutic Target For personal use only • LAG-3 is widely expressed on tumor infiltrating lymphocytes (TILs) and cytotoxic T cells → Prime target for an immune checkpoint blocker • Functionally similar to CTLA-4 (targeted by Yervoy®) and PD-1 (targeted by Keytruda®) • There are currently
Slide 6: Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications
Targeting LAG-3 May Lead to Multiple Therapeutics in Numerous Indications For personal use only IMMUNOSTIMULATION IMMUNOSUPPRESSION IMP321 APC Activator APC Agonistic mAb IMP761 MHCII Depleting LAG-3 mAb Antagonistic Partnered with mAb Partnered with LAG-3 IMP701 T-Cell T-Cell IMP731 Rheumatoid IBD
Slide 7: Oncology and Autoimmune Pipeline
Oncology and Autoimmune Pipeline* For personal use only Program Preclinical Phase I Phase II Late Stage Commercial Rights/Partners AIPAC (1) 2019 (Chemo-IO Combo) Eftilagimod Alpha TACTI-002 (2) 2019/2020 (1) § Global (LAG-3lg or IMP321), (IO-IO Combo) Rights APC activating fusion protein TACTI-mel
Slide 8: Lead Program Eftilagimod Alpha (IMP321)
For personal use only Lead Program Eftilagimod Alpha (IMP321) 8
Slide 9: Opportunity for Eftilagimod Alpha
Opportunity for Eftilagimod Alpha For personal use only Eftilagimod has the potential to be an ideal combination candidate in oncology therapy that could improve the prognosis for patients Eftilagimod Key Characteristics (based on current data): • Excellent safety profile and encouraging efficacy da
Slide 10: Eftilagimod Alpha in MBC (AIPAC)
Eftilagimod Alpha in MBC (AIPAC) (chemo-immunotherapy) For personal use only AIPAC trial (Phase IIb): Active Immunotherapy PAClitaxel, MBC patients, different EU countries Arm 1, 113 patients: Phase IIb, Safety-run in, paclitaxel + IMP321 Run-in: recommended multinational, 15 (6+9) patients, Stage 2
Slide 11: Eftilagimod Alpha Prelim. Efficacy
Eftilagimod Alpha Prelim. Efficacy Metastatic Breast Cancer For personal use only Observed response rates are substantially better than the 22-33% response rates seen in historical control groups with paclitaxel monotherapy Phase I (n=30) AIPAC – Safety Run Phase (n=15) Response Parameter Paclitaxel
Slide 12: Efti (IMP321) in Melanoma: TACTI-mel Trial Design
Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Trial Design For personal use only TACTI-mel = Two ACTive Immunotherapeutics in melanoma Recommended Phase I, multicenter, 24 patients, Efti (IMP321) + Phase II dose, open label, 4 cohorts of 6 patients anti-PD-1 (Keytruda) safety and dose esca
Slide 13: Efti (IMP321) in Melanoma: Results after Start of Combo
Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Results after Start of Combo (1) For personal use only Waterfall Plot* (starting after 4 cycles of pembrolizumab) Baseline Characteristics N = 18 (%) Elevated LDH 7 (39%) Metastasis stage M1c 15 (83 %) Pre-treated with 4 (22 %) BRAF/MEK/ipilimum
Slide 14: TACTI-mel Single Case at 1 mg efti
Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Single Case at 1 mg efti For personal use only Efficacy: Metastatic Melanoma pre-pembro week 9 (pembro) week 25 (combo) week 37 (combo) R L R L R L R L Tumor progression week 49 (Pembro mono) week 64 (PFS-FU) R L R L All lesions disappeared → CR
Slide 15: Response Analysis Starting Cycle Day 1 Pembrolizumab
Efti (IMP321) in Melanoma Response Analysis Starting Cycle 1 Day 1 Pembrolizumab For personal use only Trial Design TACTI-mel: Combination treatment of efti and pembrolizumab starts at cycle 5 in patients not responding well or progressing on pembrolizumab → difficult to compare to any historical co
Slide 16: Collaboration and Supply Agreement
Collaboration and Supply Agreement For personal use only • In March 2018 Immutep entered into clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) to evaluate the combination of eftilagimod alpha with MSD's
Slide 17: Efti (IMP321) Clinical Development: TACTI-002 Trial Design
Efti (IMP321) – Clinical Development TACTI-002 Trial Design For personal use only TACTI-002; a basket trial: Two ACTive Immunotherapeutics in different indications Efti (IMP321) + Pembrolizumab Response rate; PFS, OS, PK, Simons 2 stage; 3 Phase II, multi- (Keytruda) for 12 months + max. Biomarker;
Slide 18: Eftilagimod Alpha Partnerships
Eftilagimod Alpha Partnerships For personal use only • Eddingpharm holds Chinese rights • Chinese IND for IMP321 granted in Dec 2017 -> USD1m milestone paid to Immutep • EOC, an Eddingpharm spin-off holding the Chinese rights for IMP321, Phase I study in MBC expected to start Sep 2018 • Milestone an
Slide 19: IMP731 (Autoimmune Diseases)
For personal use only IMP731 (Autoimmune Diseases) 19
Slide 20: GSK'781 for Autoimmune Diseases
GSK‘781 for Autoimmune Diseases For personal use only GSK2831781, which is derived from IMP731 antibody, aims to kill the few activated LAG-3+ T cells that are auto-reactive in autoimmune disease leading to long term disease control without generalized immune suppression • GSK holds exclusive WWW ri
Slide 21: IMP701 (Cancer)
21 For personal use only IMP701 (Cancer)
Slide 22: IMP701 (LAG525) for Cancer
IMP701 (LAG525) for Cancer For personal use only • Novartis holds exclusive WW rights • August 2015: Start of Phase I study of IMP701 in combination with PDR001 (anti-PD-1 mAb) in 13 different cancer indications in 240 patients • 1st and 2nd Milestone payments received in Aug 2015 and August 2017, r
Slide 23: Market & Competition
For personal use only Market & Competition 23
Slide 24: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview For personal use only Immutep is the leader in developing LAG-3 modulating therapeutics Program Eftilagimod Alpha (IMP321) LAG525 (IMP701) GSK2831781 (IMP731) Relatlimab Company BMS Late stage 1 trial 1 trial 2 trials Phase 2 1 trial 4 trials 6 trials Phase 1 2 t
Slide 25: Increasing Clinical Trials Targeting LAG-3
Increasing Clinical Trials Targeting LAG-3 For personal use only Industry increasingly deploying resources to development of LAG-3 therapeutics 40 38 12,000 35 10,000 Total Estimated Patients in LAG-3 Trials 30 10,243 Number of LAG-3 Clinical Trials 8,000 25 20 20 6,000 14 15 5,630 4,000 7 10 4 4,75
Slide 26: Outlook
26 For personal use only Outlook
Slide 27: Outlook
Outlook For personal use only Immutep is well funded with a cash runway to calendar Q4 2019, well beyond the final progression free survival data from its Phase IIb AIPAC breast cancer trial. Potential News Flow and Milestones AIPAC fully recruited (226 patients): H2 2018 Clinical TACTI-mel data fro
Slide 28: Investment Highlights
Investment Highlights For personal use only The global leader in Broadest LAG-3 portfolio developing LAG-3 Deep expertise and with four product candidates, therapeutics for IP in the LAG-3 immune three of which are in nine immuno-oncology and control mechanism ongoing or planned clinical autoimmune
Slide 29: Thank you!
29 For personal use only Thank you!